Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Insights
  3. About us
MAIN/search
MAIN/Solutions
Solutions/
Solutions
  • Research and Development
  • Commercial Engagement Services
  • Consumer Health
  • MedTech
Research and Development

Local expertise and clinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.

Overview
Commercial Engagement Services

Accelerate healthcare professional and patient engagement by partnering with IQVIA’s award-winning services. Powered by unrivalled expertise and industry-leading technology, we drive design and delivery of omnichannel campaigns, end-to-end patient programs and deploy contract sales teams, ensuring your messages resonate with every audience.

Overview
Consumer Health

Providing clients in Australia and New Zealand with best practices and current local consumer health trends for over-the-counter (OTC) products. Building on their strategies faster today with tomorrow in mind.

Overview
MedTech

Local expertise with a global presence to support MedTech companies in Australia and New Zealand enhance their healthcare outcomes. Specialised to help customers who operate across medical devices, In-Vitro Diagnostics and digital health.

Overview
MAIN/Insights
Insights/
OUR LATEST WHITEPAPERS

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare, in Australia and New Zealand

Learn more
CASE STUDIES, FACTSHEETS, BLOGS & BROCHURES

Learn more
MAIN/About us
About us/
About us
White Paper
The Complexities of the Medicinal Cannabis market from an Australian viewpoint
Apr 02, 2020

Get instant access

Download

Part 1: On the fence between prescription and over-the-counter: why medicinal cannabis is a unique market segment

Introduction to the White Paper Series

Medicinal cannabis shares common characteristics with both prescription and over-the-counter (OTC) markets, making it a unique market segment with specific restrictions and complexities. Since the start of the new millennium, there has been an upturn in countries that have fully or partially de-criminalised or legalised medicinal cannabis on federal and/or regional levels. This has resulted in substantially new economic activity from what was previously an illegal trade. At present, there is no uniformity in the legalisation of medicinal cannabis across these countries. This creates complexities in a market which is somewhat burdened by limited yet growing clinical evidence. This is largely due to historical restrictions on cannabis research, and affected by concerns over the enforceability of medicinal cannabis patents. The white paper series aims to delve into these complexities by comparing the legalisation and commercialisation process of medicinal cannabis across selected countries.

Contact Us